Company / Interest Expense per Share
Neurocrine Biosciences Interest Expense per Share History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense per Share
$0.05
FY2023
5-year range
$0.05 / $0.28
FY2019-FY2023
Trend
-36.3%
vs FY2022
Sector context
#33 of 41
Health Care
What the data says
Neurocrine Biosciences's interest expense per share of $0.05 is lower than 80% of companies in the Health Care sector (FY2023). Interest Expense per Share has declined for 3 consecutive years, from $0.36 in FY2020 to $0.05 in FY2023.
Based on SEC 10-K filings.
0.05 in FY2023 with a 5-year CAGR of -32.6%.
Improved from $0.28 to $0.05 over the past 2 years.
Health Care sector context is included.
Interest Expense per Share over time
Growth rates
- 3-Year CAGR
- -48.8%
- 5-Year CAGR
- -32.6%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 41This company $0.05 Sector average $10.31
▼
-99.5% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's interest expense per share has declined for 3 consecutive years.
- In FY2023, interest expense per share decreased 36.3% year-over-year.
- Ranks #33 out of 41 companies in the Health Care sector.
- Peak interest expense per share was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest Expense per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0.05 | -36.3% |
| FY2022 | $0.07 | -72.9% |
| FY2021 | $0.28 | -22.4% |
| FY2020 | $0.36 | +0.8% |
| FY2019 | $0.35 | +2.6% |
| FY2018 | $0.34 | +52.9% |
| FY2017 | $0.22 | - |
| FY2016 | $0.00 | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026